Clinical Trial

A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP

Study acronym: ATL001-PII-CEP
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a study to investigate the effect of oral ATL-001 (ciclopirox) in CEP (Congenital Erythropoietic Porphyria) patients. During the study, it will be measured the improvement of skin lesions, fatigue and other clinical symptoms as well as blood parameters. Funding source - FDA OOPD
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-06-13; most recent amendment 2026-03-23.
Status change: Not Yet Recruiting → Recruiting 2025-12-22
Trial Details
NCT Number NCT07024316
Lead Sponsor Atlas Molecular Pharma
Conditions Congenital Erythropoietic Porphyria (CEP)
Enrollment 6 participants
Start Date 2026-01-29
Primary Completion 2028-05-01 (estimated)
Study Completion 2028-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-24